Vivos Therapeutics, Inc.

The momentum for this stock is not very good. Vivos Therapeutics, Inc. is not a good value stock. Vivos Therapeutics, Inc. is not very popular among insiders. Vivos Therapeutics, Inc. is a mediocre stock to choose.

News

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Simply Wall St Vivos Therapeutics, Inc. ( NASDAQ:VVOS ) shareholders would be excited to see that the share price has had a great...\n more…

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Ticker Report Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 15th, there was short interest totalling...\n more…

Vivos Therapeutics (NASDAQ:VVOS) Price Target Increased to $6.60 by Analysts at Ascendiant Capital Markets

Zolmax Vivos Therapeutics (NASDAQ:VVOS - Free Report) had its price target hoisted by Ascendiant Capital Markets from $6.40 to $6.60 in a report published on Tuesday morning, Benzinga reports. They...\n more…

Vivos Therapeutics (NASDAQ:VVOS) Trading 3.6% Higher

Ticker Report Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) shares shot up 3.6% during mid-day trading on Friday . The stock traded as high as $2.44 and last traded at $2.33. 22,605 shares changed hands...\n more…

Vivos Therapeutics (NASDAQ:VVOS) Shares Up 3.6%

Zolmax Vivos Therapeutics, Inc. (NASDAQ:VVOS - Get Free Report) shares traded up 3.6% during mid-day trading on Friday . The company traded as high as $2.44 and last traded at $2.33. 22,605 shares were...\n more…

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript...\n more…